부산대학교 도서관

We evaluated S-1108, a newly developed cephem antibiotic, for its in vitro antimicrobial activity, serum and sputum levels and clinical efficacy in patients with respiratory infections.The results were as follow:1. Antimicrobial activityThe minimum inhibitory concentrations (MICs) of S-1006 against 521 strains of 15 species isolated from clinical material were measured by the standard method designated by the Japan Society of Chemotherapy, and compared with those of cefteram (CFTM) and cefaclor (CCL). S-1006 showed similar or superior activity to other competitive antibiotics against methicillin -susceptible Staphylococcus aureus (MSSA). Streptococcus pneumoniae and Branhamella catarrhalis. Against gram-negative rods and Bacteroides fragilis, it showed almost the same activity as CFTM.2. Serum and sputum levelsSerum and sputum levels of S- 1006 were measured in three patients with chronic bronchitis after a single 200 mg oral dose of S-1108. The maximum serum levels were 2.1-2.6μg/ml at 2-3h after ad ministration.The maximum sputum levels were 0.11-0.20μg/ml at 2-5h after administration. The ratio of the maximum sputum level to the maximum serum level was 4.4-8.3%.3. Clinical efficacy in respiratory infectionsWe administered S-1108 150 mg b. i. d. for 7-14 days to 9 patients. Clinical efficacy was good in 7, fair in 1 and poor in 1. No adverse reactions or abnormal laboratory findings were observed.